TP53 and breast carcinoma: In addition, we show that BU-32 modulates cell-cycle-dependent kinase inhibitors, upregulates p53 and proapoptotic factors Bax and Bid, downregulates NF-κB expression at the protein level, induces apoptosis, and inhibits various angiogenic factors in a panel of breast cancer cell lines.